@kimdefalco.bsky.social"It tested a novel vaccine, based on Penn’s groundbreaking mRNA research, that trains the patient’s immune system to find and kill cancer cells.That technology has become the first mRNA cancer vaccine to succeed in a late-stage clinical trial."
@quartzmedia.bsky.socialICYMI: A cancer vaccine built for one person. Can it scale for millions? #CancerVaccine #PersonalizedMedicine
@quartzmedia.bsky.socialA cancer vaccine built for one person. Can it scale for millions? #CancerVaccine #PersonalizedMedicine
@robertlufkinmd.bsky.social
@thebabaklab.bsky.socialMerck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma.
Link in the comments 👇
#ClinicalMondays #Melanoma #CancerVaccine #mRNA #Immunotherapy
@thecancersurvivorsclub.comA personalised cancer vaccine moves another step closer. A late-stage trial of an mRNA vaccine tailored to each patient’s tumour has shown it can reduce the risk of melanoma returning or spreading.